Story perspectives

Bluebird Bio Faces Bankruptcy Risk Amid $5 Share Offer

5/15/2025

50 5

Summary

Story summary

Bluebird bio investors can opt for a revised cash offer of $5 per share from Carlyle and SK Capital Partners, valuing the company at $49 million.
This new proposal comes after challenges in securing investor backing for the initial deal, which included a contingent value right (CVR).
The tender offer period has been extended to May 29 due to insufficient shares tendered for closure.
Bluebird risks potential bankruptcy if the merger does not finalize by June 20, as stated by its board.

1 of 1

Story summary

Bluebird bio investors can opt for a revised cash offer of $5 per share from Carlyle and SK Capital Partners, valuing the company at $49 million.
This new proposal comes after challenges in securing investor backing for the initial deal, which included a contingent value right (CVR).
The tender offer period has been extended to May 29 due to insufficient shares tendered for closure.
Bluebird risks potential bankruptcy if the merger does not finalize by June 20, as stated by its board.